TOKYO -- Japanese drugmaker Eisai will make its Alzheimer's disease treatment Leqembi available for at-home administration by fiscal 2025 in the U.S., where thousands of patients are waiting to receive it, with the company planning to later roll out home use in China and India.
Pharmaceuticals
Eisai eyes fiscal 2025 U.S. approval for home version of Alzheimer's drug
Japanese pharma company looks to expand Leqembi sales with injector pen
Leqembi is injected intravenously, so patients must visit a large hospital another facility once every other week to receive it. (Eisai)
Read Next
Latest on Pharmaceuticals
